Critical appraisal of lurasidone in the management of schizophrenia
Neuropsychiatric Disease and Treatment, 04/20/2012Caccia S et al.
Lurasidone did not raise the risk of QTc interval prolongation, although additional studies are required. Long–term trials are also needed to assess the risk of new–onset diabetes. Ongoing trials in patients with bipolar disorder are being completed but, again, efficacy and safety have been investigated only in a few short–term clinical trials.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.